Finance Watch: More Biopharma Firms Join The IPO Queue
Public Company Edition: With investor interest in drug developer initial public offerings rising, more firms have filed to go public, including BlossomHill, Vogenx, Braveheart, Attovia and Apnimed. Also, Erasca raised $632.5m in a follow-on offering, while Inhibrx expanded a debt deal to $500m.
Scrip - July 17, 2026

Biogen Aims For ‘No Disruption’ Integrating Apellis
Biogen president and head of North America Alisha Alaimo talked with Scrip about the company’s next steps in kidney disease and ophthalmology after buying Apellis.
Scrip - July 17, 2026

Scrip Deals Podcast: Why Are Biopharma M&A Deals Closing More Quickly?
Scrip discusses the recent trend of M&A deals valued at $1bn or greater closing much more quickly than they did during 2023-2025 with Neurvati CEO Bruce Leuchter.
Scrip - July 17, 2026

Wegovy Adds Liver Indication In India – Can Novo Nordisk Outrun Generics?
India greenlights Wegovy for MASH but can Novo Nordisk turn the new indication into a competitive moat quickly amid concerns of off label use and heightened competition in the obesity and diabetes segments?
Scrip - July 17, 2026

Alzheimer’s AAIC Video Interview: Eisai Looks To Extend Leqembi Lead With Tau-Targeting Combo
Eisai's Michael Irizarry on broadening Leqembi's use with its subcutaneous version, an ongoing Phase III trial in treating patients before dementia symptoms appear and news from a Phase II study of its tau-targeting asset, etalanetug.
Scrip - July 17, 2026

GSK’s Camlipixant Scrapped After Coughing Up Mixed Results
Camlipixant's failure leaves chronic cough without a late-stage contender, and GSK leaning harder on oncology.
Scrip - July 17, 2026

Where Need Leads: Why Patient Journey Should Help Shape Innovation Priorities
Innovation has traditionally been guided by scientific opportunity—but should patient burden play a greater role in determining where innovation is needed most?
Scrip - July 17, 2026

Intuitive Surgical Posts Strong Q2 Revenues, Moves Into GI Endoscopy With FDA Submission
Intuitive Surgical reported strong second-quarter results with 19% revenue growth and 16% procedure growth. The medical robotics leader also disclosed an FDA 510(k) submission for a non-commercial flexible robotic endoscope for the gastrointestinal (GI) tract.
Medtech Insight - July 18, 2026

FDA Targets November For Cosmetic Rulemakings; EU Coalition Seeks E-Commerce Fix
The US FDA has again pushed back its expected rulemaking on fragrance allergen labeling and formaldehyde in heated hair smoothing products. Separately, a coalition of European industry and environmental groups asks regulators to hold e-commerce sellers accountable for compliance with EU rules.
HBW Insight - July 17, 2026

EU Proposes New Cosmetic Ingredient Bans, Restrictions
The EU is proposing new bans and restrictions on cosmetic ingredients following recent SCCS safety opinions.
HBW Insight - July 17, 2026

Samsung Bioepis And Organon Deepen Australian Ties With A New Biosimilar Deal
Determined to bring savings to Australia’s Pharmaceutical Benefits Scheme, Samsung Bioepis and Organon have expanded their local partnership with a new undisclosed biosimilar product.
Generics Bulletin - July 17, 2026

South Africa’s Semaglutide Market Opens To Generic Competition
Sun Pharma has become the first manufacturer after Novo Nordisk to secure a South African semaglutide approval, intensifying competition as rivals including Aspen, Natco and Lupin prepare their own market entries.
Generics Bulletin - July 17, 2026

Celltrion Trims Oncology Trials, Doubles Down On Immunology
Celltrion is resizing late-stage biosimilar trials as regulators ease evidence expectations, while advancing guselkumab into Phase I studies and broadening its autoimmune pipeline.
Generics Bulletin - July 17, 2026

States Extract Millions From Glenmark Over US Pricing Conspiracy
Glenmark will pay about $29.6m to settle multi-state claims it helped inflate generic drug prices, while consumers move closer to restitution and wider litigation continues.
Generics Bulletin - July 17, 2026

The Capsid Evangelist: How Dyno’s Eric Kelsic Is Making The Case For AAV At Its Lowest Ebb
Dyno Therapeutics' CEO Eric Kelsic is trying to engineer better AAV capsids, licensing them to partners and betting that superior gene-delivery tools will revive gene therapy.
In Vivo - July 17, 2026

How BioNTech’s Commercial Chief Plans To Launch Into Oncology’s Most Crowded Bispecific Race
As it comes closer to seeking regulatory approval for its first cancer drugs – delivering on its promise to be a multi-product oncology company by 2030 – BioNTech brought on Annemarie Hanekamp to get the company ready for commercialization.
In Vivo - July 17, 2026